Floatz logo

Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre

Gastric Adenocarcinoma

Thomas Jefferson UniversityvaccinePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

64 Active assets in the Gastric Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Boehringer Ingelheim
Phase 3BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
TRASTUZUMAB
Boehringer Ingelheim
Phase 2BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre is also rated in:

esophageal adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
gastric cancerDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →